Cargando…

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs

High-dose melphalan with autologous stem cell rescue has been regarded as the standard of care for patients with newly diagnosed myeloma up to the age of 65–70 years. The recent development of agents with potent anti-tumor activity such as thalidomide, lenalidomide and bortezomib has further improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruno, Benedetto, Giaccone, Luisa, Festuccia, Moreno, Boccadoro, Mario
Formato:	Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2010
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033139/ https://www.ncbi.nlm.nih.gov/pubmed/21415966 http://dx.doi.org/10.4084/MJHID.2010.013

Ejemplares similares

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
por: Pittari, Gianfranco, et al.
Publicado: (2017)

Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
por: Mussetti, Alberto, et al.
Publicado: (2020)

Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?
por: Lia, Giuseppe, et al.
Publicado: (2021)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications
por: Lia, Giuseppe, et al.
Publicado: (2020)

Recurrent Plasmacytomas after Allografting in a Patient with Multiple Myeloma
por: Stawis, Allen N., et al.
Publicado: (2012)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
por: Aydin, Semra, et al.
Publicado: (2020)

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era
por: Maura, Francesco, et al.
Publicado: (2016)

Multiple myeloma and kidney transplantation: the beginning of a new era
por: Van den bosch, Ines, et al.
Publicado: (2019)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

The Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma: A Systematic Review of the Literature
por: Khorochkov, Arseni, et al.
Publicado: (2021)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
por: D’Agostino, Mattia, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
por: Luoma, Sini, et al.
Publicado: (2021)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach
por: Giaccone, Luisa, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
por: Marangon, Miriam, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine
por: Shimazu, Yutaka, et al.
Publicado: (2021)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Nozzoli, C., et al.
Publicado: (2023)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era
por: Morello, Enrico, et al.
Publicado: (2018)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ckqgks6jbd3mkp4fvd77jqhu68